Benzo[b]pyrano[3,2-h]acridin-7-one compounds
    21.
    发明授权
    Benzo[b]pyrano[3,2-h]acridin-7-one compounds 失效
    苯并[b]吡喃并[3,2-h]吖啶-7-酮化合物

    公开(公告)号:US06642248B2

    公开(公告)日:2003-11-04

    申请号:US10205566

    申请日:2002-07-25

    IPC分类号: A61K314741

    CPC分类号: C07D491/04

    摘要: A compound selected from those of formula (I): wherein: X and Y represent group selected from hydrogen, halogen, mercapto, cyano, nitro, alkyl, trihaloalkyl, trihaloalkylcarbonylamino, —ORa, —NRaRb, —NRa—C(O)—T1, —O—C(O)—T1, —O—T2-NRaRb, —O—T2-ORa, —NRa—T2-NRaRb, —NRa—T2-ORa and —NRa—T2-CO2Ra wherein Ra, Rb, T1, T2 are as defined in the description, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, —ORa, —NRaRb, —NRa—C(O)—T1, —O—C(O)—T1, —O—T2-NRaRb, —O—T2-ORa, —NRa—T2-NRaRb, —NRa—T2-ORa and —NRa—T2-CO2Ra wherein Ra, Rb, T1 and T2 are as defined hereinbefore, R3 and R4 represent hydrogen or alkyl, W represents a group of formula —CH(R5)—CH(R6)—, —CH═C(R7)—, —C(R7)═CH— or —C(O)—CH(R8)— wherein R5, R6, R7 and R8 are as defined in the description, their isomers and N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

    摘要翻译: 选自式(I)的化合物:其中:X和Y表示选自氢,卤素,巯基,氰基,硝基,烷基,三卤代烷基,三卤代烷基羰基氨基,-OR a,-NR a R b,-NR a -C(O) - T1,-OC(O)-T1,-O-T2-NRaRb,-O-T2-ORa,-NRa-T2-NRaRb,-NRa-T2-ORa和-NRa-T2-CO2Ra,其中Ra,Rb,T1 ,T 2如说明书中所定义,R 1表示氢或烷基,R 2表示选自氢,-OR a,-NR a R b,-NR a -C(O)-T1,-OC(O)-T1,-O- R2-NRaRb,-O-T2-ORa,-NRa-T2-NRaRb,-NRa-T2-ORa和-NRa-T2-CO2Ra,其中Ra,Rb,T1和T2如上所定义,R3和R4代表氢或 烷基,W表示式-CH(R 5)-CH(R 6) - , - CH = C(R 7) - , - C(R 7)= CH-或-C(O)-CH(R 8) R5,R6,R7和R8如说明书中所定义,它们的异构体和N-氧化物及其与药学上可接受的酸或碱的加成盐,以及含有它们的药物,可用于治疗癌症。

    12,13-(pyranosyl)-indolo[2,3-a]pyrrolo[3,4-c]carbazole and 12,13-(pyranosyl)-furo[3,4-c]indolo[2,3-a]carbazoles
    22.
    发明授权
    12,13-(pyranosyl)-indolo[2,3-a]pyrrolo[3,4-c]carbazole and 12,13-(pyranosyl)-furo[3,4-c]indolo[2,3-a]carbazoles 失效
    12,13-(吡喃糖基) - 吲哚并[2,3-a]吡咯并[3,4-c]咔唑和12,13-(吡喃糖基) - 呋喃并[3,4-c]吲哚并[2,3-a] 咔唑

    公开(公告)号:US06569858B2

    公开(公告)日:2003-05-27

    申请号:US10010379

    申请日:2001-11-05

    IPC分类号: C07D49044

    CPC分类号: C07H19/23

    摘要: A compound selected from those of formula (I): wherein: R1 and R2, which may be identical or different, represent a group of formula U-V wherein U represents single bond, or alkylene which is optionally substituted and/or unsaturated, and V is as defined in the description, G represents oxygen, or NR3 wherein R3 is as defined in the description, X represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y represents hydrogen, or X+Y represents carbonyl, X1 represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y1 represents hydrogen, or X1+Y1 represents carbonyl, R4, R5, and R6 are as defined in the description, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same are useful in the treatment of cancer.

    摘要翻译: 选自式(I)的化合物:其中:R 1和R 2可以相同或不同,表示其中U表示单键的式UV基团,或任选被取代和/或不饱和的亚烷基,V是 G表示氧或NR 3,其中R3如说明书中所定义,X表示氢,羟基,烷氧基,巯基或烷硫基,Y表示氢,或X + Y表示羰基,X1表示氢,羟基, 烷氧基,巯基或烷硫基,Y1表示氢,或X1 + Y1表示羰基,R4,R5和R6如说明书中所定义,其异构体及其药学上可接受的酸或碱加成盐,以及含有它们的药物 可用于治疗癌症。

    Compounds of 7-oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin carboxylate
    23.
    发明授权
    Compounds of 7-oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin carboxylate 失效
    7-氧代-2,3,7,14-四氢-1H-苯并[b]吡喃并[3,2-h]吖啶羧酸酯的化合物

    公开(公告)号:US06503919B1

    公开(公告)日:2003-01-07

    申请号:US09594853

    申请日:2000-06-15

    IPC分类号: C07D491052

    CPC分类号: C07D491/04

    摘要: A compound selected from those of formula (I): wherein: X and Y represent hydrogen, halogen, hydroxy, mercapto, cyano, nitro, alkyl, alkoxy, trihaloalkyl, optionally substituted amino, methylenedioxy, or ethylenedioxy, R1 represents hydrogen, or alkyl, R2 represents hydrogen, hydroxy, alkyl, alkoxy, alkylcarbonyloxy, or optionally substituted amino, R3 and R4 represent hydrogen, or alkyl, R5 and R6 represent —O—CO—U—V wherein U and V are as defined in the description, or Z as defined in the description, it being understood that at least one of the R5 and R6 groups represents —O—CO—U—V, their isomers, N-oxides, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of cancer.

    摘要翻译: 选自式(I)的化合物:其中:X和Y表示氢,卤素,羟基,巯基,氰基,硝基,烷基,烷氧基,三卤代烷基,任选取代的氨基,亚甲二氧基或亚乙二氧基, ,R 2表示氢,羟基,烷基,烷氧基,烷基羰基氧基或任选取代的氨基,R 3和R 4表示氢或烷基,R 5和R 6表示-O-CO-UV,其中U和V如说明书中所定义,或Z 可以理解的是,R 5和R 6基团中的至少一个表示-O-CO-UV,它们的异构体,N-氧化物及其药学上可接受的酸或碱加成盐,以及含有 相同的可用于治疗癌症。

    Peptide compounds analogues of the glucagon-like peptide-1 (7-37)
    28.
    发明授权
    Peptide compounds analogues of the glucagon-like peptide-1 (7-37) 失效
    胰高血糖素样肽-1(7-37)的肽化合物类似物

    公开(公告)号:US06620910B1

    公开(公告)日:2003-09-16

    申请号:US09268578

    申请日:1999-03-15

    IPC分类号: A61K3816

    CPC分类号: C07K14/605 A61K38/00

    摘要: Compound of formula (I): Z1-X1-X2-X3-Gly-Thr-Phe-Thr-Ser-X4-X5-Ser-X6-X7-X8  (I) wherein: Z1, substituent of the terminal amino group, represents hydrogen, alkyl or acyl, or arylcarbonyl, heteroarylcarbonyl, arylalkylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, arylalkoxycarbonyl or alkoxycarbonyl each of which is optionally substituted, Z2 (SEQ ID NO: 1), substituent of the terminal carbonyl group, represents hydroxy, alkoxy or optionally substituted amino, X1 to X14 each represents an amino acid residue having the D or L configuration as defined in the description, X15 represents a bond or an arginine residue (Arg). Medicinal products containing the same are useful as tGLP-1 agonists.

    摘要翻译: 式(I)的化合物:其中:Z 1,末端氨基的取代基代表氢,烷基或酰基,或芳基羰基,杂芳基羰基,芳基烷基羰基,杂芳基羰基,芳氧基羰基,芳基烷氧基羰基或烷氧基羰基,其各自任选被取代,Z2(SEQ ID NO:1),末端羰基的取代基表示羟基,烷氧基或任选取代的氨基,X 1至X 14各自表示具有如说明书中所定义的D或L构型的氨基酸残基,X 15表示键或精氨酸残基 (Arg)。含有它们的药物可用作tGLP-1激动剂。

    Acronycine derivatives, preparation method and pharmaceutical compositions
    29.
    发明授权
    Acronycine derivatives, preparation method and pharmaceutical compositions 失效
    Acronycine衍生物,制备方法和药物组合物

    公开(公告)号:US06288073B1

    公开(公告)日:2001-09-11

    申请号:US09581853

    申请日:2000-06-19

    IPC分类号: A61K314741

    CPC分类号: C07D491/04 C07D491/14

    摘要: A compound selected from those of formula (I): in which: X and Y represent hydrogen, halogen, hydroxy, mercapto, cyano, nitro, alkyl, alkoxy, trihaloalkyl, optionally substituted amino, methylenedioxy, or ethylenedioxy, R1 represents hydrogen, or alkyl, R2 represents hydrogen, hydroxy, alkyl, alkoxy, alkylcarbonyloxy, or optionally substituted ammo, R3 and R4 represent hydrogen, or alkyl, A represents —CH═CH—, or —CH(R5)—CH(R6)— wherein R5 and R6 are as defined in the description, their isomers, N-oxides, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of cancer.

    摘要翻译: 选自式(I)的化合物:其中:X和Y表示氢,卤素,羟基,巯基,氰基,硝基,烷基,烷氧基,三卤代烷基,任选取代的氨基,亚甲二氧基或亚乙二氧基, 烷基,R 2表示氢,羟基,烷基,烷氧基,烷基羰基氧基或任选取代的氨基,R3和R4表示氢或烷基,A表示-CH = CH-或-CH(R5)-CH(R6) - ,其中R5 和R6如说明书中所定义,它们的异构体,N-氧化物及其药学上可接受的酸或碱加成盐,以及其可用于治疗癌症的药物。